Feb 20, 2019 - Johnson & Johnson said it received subpoenas from the Justice Department and the Securities and Exchange Commission seeking documents related to the safety of its baby powder and other talc-containing products.
Feb 14, 2019 - Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Feb 05, 2019 - Under pressure over rising drug prices, pharmaceutical companies are pushing a new defense: They’re not raising prices to make money or to cover research costs, but rather to pay a cut to middlemen in the supply chain.
Jan 30, 2019 - Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
Jan 30, 2019 - Here's why some of the industry's largest players are telling investors not to expect any fireworks this year.
Jan 29, 2019 - Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.
Jan 29, 2019 - With nearly four dozen securities in Berkshire Hathaway's portfolio, these may be next on the chopping block.
Jan 28, 2019 - Top Research Reports for Johnson & Johnson, Boeing & Starbucks
Jan 28, 2019 - Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
Jan 25, 2019 - J&J (JNJ) and Bristol-Myers (BMY) kick off earnings for pharma sector. Lilly (LLY) and AbbVie (ABBV) announce failure of late-stage studies.